 SAN DIEGO, June 01, 2022 GLOBE NEWSWIRE -- BioAtla, Inc. Nasdaq: BCAB, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic CAB antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder, and Scott Smith, President, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in-person in New York, NY June 8-10, 2022. 